Cebelia, from Paris, France, along with CNRS/ INSERM develop innovative technology with an objective to discover agents that will be effective in treating damaged skin. Cebelia holds a patent on Cebeline® (a peptide fragment of Laminin-5) that accelerates skin healing, replacing its absent or deficient native counterpart and Pekaline®- which disrupts melanin production on two levels and helps eliminate spots.
1 product